EQS News and Press, Equus Total Return Inc.

Equus Total Return Inc. (EQS) is expected to report for Q4 2023

2024-04-03 09:08:30 ET Read the full article on Seeking Alpha For further details see: Equus Total Return posts NAV per share of $3.55

2024-02-14 12:00:23 ET More on Financials: XLF: Far More Than Banks XLF: How Exposed Is It To Inflation And Fluctuating Rates? XLF: The 2024 Financials Sector Outlook Is Concerning Riot, CleanSpark, Marathon dominate week's financial gainers amid bitcoin rall...

HOUSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) ("Equus") today announced that its wholly-owned subsidiary Morgan E&P, LLC ("Morgan"), has received from Cawley, Gillespie & Associates, Inc. (“CG&A”) an updated reserve estimate as of Januar...

Completes Sale of Wellbore Working Interest For $5.6 Million Gross Oil Production Over 1,000 Barrels Per Day HOUSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Equus Total Return, Inc. (NYSE: EQS) ("Equus") today announced that Morgan E&P, LLC ("Morgan"), a wholly-owned subsidia...

HOUSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) ("Equus") today announces that Morgan E&P, LLC, ("Morgan"), a wholly-owned subsidiary of Equus, continues to acquire mineral rights in the Bakken/Three Forks formation in the Williston Basin of North Dakota. Morga...

BASEL, SWITZERLAND / ACCESSWIRE / December 18, 2023 / Chile's Internal Revenue Authority (Servicio de Impuestos Internos, SII) awarded the contract to fight illicit trade of cigarettes in Chile to SICPA for another five years, starting from 2024. The solution, called Sistema de Trazabilidad Fisc...

2023-11-15 03:26:17 ET More on Equus Total Return For further details see: Equus Total Return reports net assets of $47.1M

HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of September 30, 2023, of $47.1 million. Net asset value per share increased to $3.49 as of September 30, 2023, from $2.96 as of June 30...

Brings over 20 years of clinical experience, including management of Phase 1-2 clinical trials in a variety of indications such as ophthalmology Will oversee all R&D operations with focus on clinical development and operations KENSINGTON, MD / ACCESSWIRE / October 25, 2023 / Galime...